A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Studies on Ivermectin Against COVID-19 | Date | Journal | Participants | Outcome | ||||||||||||||||||||
2 | Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study | 2020 | Biomedical Research | 35 | Positive | ||||||||||||||||||||
3 | Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management | July 8, 2020 | Preprint | 87 | Positive | ||||||||||||||||||||
4 | Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirin Against COVID-19 | Sept. 15, 2020 | Preprint | 167 | Positive | ||||||||||||||||||||
5 | Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel | Nov. 17, 2020 | Journal of Biomedical Research and Clinical Investigation | 229 | Positive | ||||||||||||||||||||
6 | Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial | Feb. 1, 2021 | Journal of Clinical and Diagnostic Research | 203 contacts to 52 index cases | Positive | ||||||||||||||||||||
7 | Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease | Feb. 5, 2021 | Preprint | 86 | Positive | ||||||||||||||||||||
8 | A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients | Feb. 25, 2021 | Eurasian Journal of Medicine and Oncology | 116 | Positive | ||||||||||||||||||||
9 | Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial | May 2021 | International Journal of International Medical Research | 363 | Positive | ||||||||||||||||||||
10 | Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19 | May 2021 | Journal of Medical Virology | 113 | Positive | ||||||||||||||||||||
11 | Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq | May 6, 2021 | Iraqi Journal of Medical Sciences | 140 | Positive | ||||||||||||||||||||
12 | Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19 | June 15, 2021 | International Journal of Nanomedicine | 114 | Positive | ||||||||||||||||||||
13 | Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study | Aug. 13, 2021 | Cureus | 271 | Positive | ||||||||||||||||||||
14 | Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina | Sept-Oct, 2021 | American Journal of Therapeutics | 234 | Positive | ||||||||||||||||||||
15 | Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients | Feb. 9, 2022 | Future Microbiology | 24 | Positive | ||||||||||||||||||||
16 | Randomized trials – Ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers | June 21, 2022 | Research, Society and Development | 254 | Positive | ||||||||||||||||||||
17 | The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial | July 7, 2022 | International Journal of Infectious Diseases | 89 | Positive | ||||||||||||||||||||
18 | The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial | Feb. 1, 2021 | The Lancet | 24 | Mixed | ||||||||||||||||||||
19 | Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial | April 2021 | International Journal of Infectious Diseases | 3037 | Mixed | ||||||||||||||||||||
20 | Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study | June 2, 2021 | Journal of Medical Virology | 164 | Mixed | ||||||||||||||||||||
21 | Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial | July 1, 2021 | The Lancet | 45 | Mixed | ||||||||||||||||||||
22 | Ivermectin compared with placebo in the clinical evolution of Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial | May 23, 2022 | Preprint | 66 | Mixed | ||||||||||||||||||||
23 | Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial | Aug. 26, 2022 | Trials | 72 | Mixed | ||||||||||||||||||||
24 | Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial | Feb. 23, 2021 | Infectious Disease Reports | 106 | Not Supportive | ||||||||||||||||||||
25 | Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 | March 4, 2021 | Journal of American Medical Association | 476 | Not Supportive | ||||||||||||||||||||
26 | Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients | May 4, 2021 | BMC Infectious Diseases | 66 | Not Supportive | ||||||||||||||||||||
27 | Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial | July 2, 2021 | BMC Infectious Diseases | 501 | Not Supportive | ||||||||||||||||||||
28 | Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities | Feb. 18, 2022 | Journal of American Medical Association | 490 | Not Supportive | ||||||||||||||||||||
29 | Effect of combined use of ivermectin and colchicine in COVID-19 patients | June 22, 2022 | Egyptian Journal of Anesthesia | 135 | Not Supportive | ||||||||||||||||||||
30 | Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19 | July 19, 2022 | Preprint | 96 | Not Supportive | ||||||||||||||||||||
31 | Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 | Aug. 18, 2022 | New England Journal of Medicine | 1323 | Not Supportive | ||||||||||||||||||||
32 | Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial | Oct 20, 2022 | Expert Review of Anti-infective Therapy | unclear | Not Supportive | ||||||||||||||||||||
33 | Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 | Oct. 25, 2022 | Journal of American Medical Association | 1591 | Not Supportive | ||||||||||||||||||||
34 | |||||||||||||||||||||||||
35 | |||||||||||||||||||||||||
36 | |||||||||||||||||||||||||
37 | |||||||||||||||||||||||||
38 | |||||||||||||||||||||||||
39 | |||||||||||||||||||||||||
40 | |||||||||||||||||||||||||
41 | |||||||||||||||||||||||||
42 | |||||||||||||||||||||||||
43 | |||||||||||||||||||||||||
44 | |||||||||||||||||||||||||
45 | |||||||||||||||||||||||||
46 | |||||||||||||||||||||||||
47 | |||||||||||||||||||||||||
48 | |||||||||||||||||||||||||
49 | |||||||||||||||||||||||||
50 | |||||||||||||||||||||||||
51 | |||||||||||||||||||||||||
52 | |||||||||||||||||||||||||
53 | |||||||||||||||||||||||||
54 | |||||||||||||||||||||||||
55 | |||||||||||||||||||||||||
56 | |||||||||||||||||||||||||
57 | |||||||||||||||||||||||||
58 | |||||||||||||||||||||||||
59 | |||||||||||||||||||||||||
60 | |||||||||||||||||||||||||
61 | |||||||||||||||||||||||||
62 | |||||||||||||||||||||||||
63 | |||||||||||||||||||||||||
64 | |||||||||||||||||||||||||
65 | |||||||||||||||||||||||||
66 | |||||||||||||||||||||||||
67 | |||||||||||||||||||||||||
68 | |||||||||||||||||||||||||
69 | |||||||||||||||||||||||||
70 | |||||||||||||||||||||||||
71 | |||||||||||||||||||||||||
72 | |||||||||||||||||||||||||
73 | |||||||||||||||||||||||||
74 | |||||||||||||||||||||||||
75 | |||||||||||||||||||||||||
76 | |||||||||||||||||||||||||
77 | |||||||||||||||||||||||||
78 | |||||||||||||||||||||||||
79 | |||||||||||||||||||||||||
80 | |||||||||||||||||||||||||
81 | |||||||||||||||||||||||||
82 | |||||||||||||||||||||||||
83 | |||||||||||||||||||||||||
84 | |||||||||||||||||||||||||
85 | |||||||||||||||||||||||||
86 | |||||||||||||||||||||||||
87 | |||||||||||||||||||||||||
88 | |||||||||||||||||||||||||
89 | |||||||||||||||||||||||||
90 | |||||||||||||||||||||||||
91 | |||||||||||||||||||||||||
92 | |||||||||||||||||||||||||
93 | |||||||||||||||||||||||||
94 | |||||||||||||||||||||||||
95 | |||||||||||||||||||||||||
96 | |||||||||||||||||||||||||
97 | |||||||||||||||||||||||||
98 | |||||||||||||||||||||||||
99 | |||||||||||||||||||||||||
100 |